GHRS — GH Research PLC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855129 ·
Last close
$18.27
Market Cap
$1.25B
52W High
$31.44
52W Low
$12.04
ADV30
332,997
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -15,352,000 | -12,450,000 | 359,912,000 | 345,088,000 | 10,892,000 |
| Jun 2026 | 0 | — | -19,448,000 | -15,146,000 | 372,349,000 | 345,053,000 | 12,859,000 |
| Mar 2026 | 0 | — | -18,748,000 | -18,967,000 | 275,267,000 | 242,652,000 | 11,890,000 |
| Dec 2025 | 0 | — | -16,699,000 | -14,137,000 | 288,230,000 | 246,251,000 | 8,527,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,703,000
Investing CF
$33,605,000
Financing CF
$111,736,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.92
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-187,836,000
Inventory
—
Receivables
$1,295,000
ST Investments
$17,597,000
EBIT TTM
$-62,242,000
Pretax Income TTM
$-62,270,000
Interest Exp TTM
$28,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -60,676,000 | -48,258,000 | 288,230,000 | 8,527,000 | 279,703,000 | -43,552,000 |
| Dec 2024 | 0 | -50,246,000 | -38,961,000 | 188,273,000 | 9,322,000 | 178,951,000 | -42,285,000 |
| Dec 2023 | 0 | -41,221,000 | -35,587,000 | 226,300,000 | 7,332,000 | 218,968,000 | -33,336,000 |
| Dec 2022 | 0 | -30,675,000 | -22,456,000 | 254,362,000 | 4,546,000 | 249,816,000 | -26,199,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.85
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.50 · spot: $18.25 · call volume: 36 · put volume: 6
Expected Move to 2027-01-15:
±$16.13
(88.38%) —
implied range
$2.12 –
$34.38
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.24B | $27.92 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
| GENB | Generate Biomedicines, Inc. | $1.27B | $9.84 | — |
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| SLN | Silence Therapeutics plc | $1.23B | $19.80 | — |
News headlines (Yahoo Finance, 1h cache)
Is GH Research (GHRS) Overvalued Even After Positive FDA Feedback?
2026-11-16 23:24 · Yahoo
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-13 13:00 · Yahoo
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
2026-11-13 12:55 · Yahoo
GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger
2026-11-01 23:24 · Yahoo
Is GH Research (GHRS) Trading At A Premium To Fair Value?
2026-08-02 18:09 · Yahoo
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
2026-07-16 10:33 · Yahoo
GH Research Announces Publication of Phase 2a Postpartum Depression Results
2026-06-04 11:00 · Yahoo
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
2026-08-25 14:31 · Yahoo
GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price
2026-10-18 22:07 · Yahoo
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.